70 to 80% of the global population lives with a known chronic disease. Most of them won't know something is wrong until symptoms appear, often years after the biology has already shifted.
Dr. Guru Banavar, Founding CTO of Viome, joins host Brian Chee on HumanifAI HealthTech to break down how Viome's molecular AI reads RNA from gut, blood, and saliva samples to detect biological dysfunction before disease sets in, and why the distinction between what DNA knows and what RNA reveals in real time is the key to making preventive medicine work at scale.
---
🎙 ABOUT DR. GURU BANAVAR
Guru is the founding CTO of Viome, where he leads AI and discovery. Viome uses host and microbiome gene expression to deliver precision nutrition and supplements aimed at deterring chronic disease. His work at Viome includes biomarker discovery, therapeutic target identification across metabolic, gastrointestinal, autoimmune, and neurological disorders, and the development of a saliva-based early detection system for oral and throat cancers — now an FDA breakthrough-designated product. Prior to Viome, he served as Global VP and Chief Science Officer at IBM, where he founded the Watson AI Research team and led hundreds of researchers in building AI systems across healthcare, education, finance, and law. He holds a PhD in Computer Science and 35+ US patents.
🎙 ABOUT HUMANIFAI HEALTHTECH:
HumanifAI HealthTech explores how AI is rewriting the rules of healthcare and putting people back at the center where they belong.
Hosted by Brian Chee, Senior Director of Content Strategy and Communications at Net Health, the show features candid conversations with the people leading the charge on AI across healthcare and tech.
Podden och tillhörande omslagsbild på den här sidan tillhör
Net Health. Innehållet i podden är skapat av Net Health och inte av,
eller tillsammans med, Poddtoppen.
